BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11672551)

  • 1. A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control.
    Fruzzetti F; Genazzani AR; Ricci C; De Negri F; Bersi C; Carmassi F
    Contraception; 2001 Jun; 63(6):303-7. PubMed ID: 11672551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of two low-dose gestodene containing monophasic oral contraceptives on hemostasis in Bulgarian women.
    Uchikova E; Pehlivanov B
    Expert Opin Pharmacother; 2008 Aug; 9(11):1839-44. PubMed ID: 18627323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH; Schindler AE; Endrikat J; Düsterberg B
    Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of a low-dose contraceptive--Femodene].
    Rachev E; Damianov L; Dukovski A; Katsarova M
    Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():9-15. PubMed ID: 14677620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women.
    Oosterbaan HP
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():3-8. PubMed ID: 14677619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
    Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.
    van der Mooren MJ; Klipping C; van Aken B; Helmerhorst E; Spielmann D; Kluft C
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():27-35. PubMed ID: 14677622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
    Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
    Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
    Prasad RN; Koh SC; Viegas OA; Ratnam SS
    Clin Appl Thromb Hemost; 1999 Jan; 5(1):60-70. PubMed ID: 10725985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
    Hamerlynck JV; Vollebregt JA; Doornebos CM; Muntendam P
    Contraception; 1987 Mar; 35(3):199-205. PubMed ID: 2956054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gynera).
    Taneepanichskul S; Kriengsinyot R; Jaisamrarn U
    Contraception; 2002 Dec; 66(6):407-9. PubMed ID: 12499032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemostatic balance during treatment with the newest contraceptives].
    Petersen KR; Skouby SO; Sidelmann J; Jespersen J
    Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.